mRNA-1273.529
- Generic Name
- mRNA-1273.529
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: BNT162b2 (B.1.1.529)Biological: BNT162b2 bivalent (wildtype and Omicron BA.1)Biological: BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)Other: Sodium Chloride, 0.9%Biological: BNT162b2 (B.1.351)Biological: CoV2 preS dTM/D614Biological: CoV2 preS dTM [B.1.351]Biological: CoV2 preS dTM/D614+B.1.351
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2025-03-14
- Target Recruit Count
- 1270
- Registration Number
- NCT05289037
- Locations
- 🇺🇸
University of California, San Diego (UCSD) - Antiviral Research Center (AVRC), San Diego, California, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham, Alabama, United States
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
Phase 2
Completed
- Conditions
- SARS-CoV-2
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 5161
- Registration Number
- NCT04927065
- Locations
- 🇺🇸
Research Centers of America, Hollywood, Florida, United States
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
🇺🇸Meridian Clinical Research (Iowa), Sioux City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath